Table 3 Study sample characteristics (number, %)
From: Generating evidence on a risk-based monitoring approach in the academic setting – lessons learned
Total | |||
|---|---|---|---|
n | % | ||
Total studies | 43 | 100 | |
Study design | Interventional | 34 | 79.1 |
Observational | 9 | 20.9 | |
Study type | Multicenter | 10 | 23.3 |
Singlecenter | 33 | 76.7 | |
Study sponsor | Investigator (academic) | 40 | 93.0 |
Industry | 3 | 7.0 | |
Type of research | Drug | 29 | 67.4 |
Medical Device | 5 | 11.6 | |
Biological Samplesa | 4 | 9.4 | |
Otherb | 5 | 11.6 | |
Study phase (drug studies, n = 29) | I | 9 | 31.1 |
II | 7 | 24.1 | |
III | 8 | 27.6 | |
IV | 3 | 10.3 | |
Otherc | 2 | 6.9 | |